Key Highlights

● Nexalin's June 2026 Brazil pilot study showed a 77.8% anxiety response rate for its drug-free neurostimulation device, but the clinical progress is now overshadowed by a July 24 Nasdaq staff determination threatening to suspend NXL trading on August 4, 2026.

● As of March 31, 2026, Nexalin held $1.21 million in cash plus $1.50 million in short-term investments, against current liabilities of $808,364.

● The most immediate risk is binary: absent Nasdaq Hearings Panel relief, NXL would be suspended from trading August 4, 2026 and likely move to over-the-counter markets.

● Investors should watch for the Nasdaq Hearings Panel's decision ahead of the August 4, 2026 suspension date.

Nexalin Technology, Inc. (Nasdaq: NXL), a Houston developer of non-invasive deep intracranial frequency stimulation (DIFS) devices for anxiety, depression and insomnia, disclosed topline results on June 10, 2026 from an open-label pilot trial in Brazil, reporting a 77.8% anxiety response rate plus gains in depression and sleep quality. The news lands at a pivotal moment: the small-cap medtech is pursuing FDA clearance for its HALO Clarity insomnia device while fighting to keep NXL listed on Nasdaq. On July 24, 2026, Nasdaq staff determined Nexalin had failed to regain bid-price compliance, setting an August 4, 2026 suspension date the company is now appealing. The mix of encouraging clinical signals and existential listing risk frames the investment case.

What happened

On June 10, 2026, Nexalin announced results from an eight-week, open-label pilot study at the Institute of Psychiatry, University of São Paulo, testing its Gen-2 DIFS device (15 mA, 77.5 Hz) in patients with generalized anxiety and comorbid insomnia over 20 sessions across four weeks. Nexalin reported a 77.8% anxiety response rate, an 18.30-point Hamilton Anxiety Rating Scale reduction by session 20 (versus 14.73 at session 5), a 66.7% depression response/remission rate, and sleep-quality gains with "large effect sizes" on the Pittsburgh Sleep Quality Index. No serious adverse events, seizures or manic/hypomanic switches were reported. Because the study was open-label, lacked a placebo arm, and did not disclose patient count, results should be read as preliminary. Nexalin is preparing a Brazil product launch, where the device is already approved, alongside China, Oman and Israel.

Why the development matters

The Brazil data, while early-stage, add to studies Nexalin has publicized in 2026, including an April peer-reviewed neuroimaging paper on chronic insomnia, supporting its broader FDA strategy for HALO Clarity and a planned Alzheimer's program. Signals from an already-approved market may help build a case for the device's mechanism ahead of a rigorous, blinded U.S. trial. But the delisting threat is more consequential near term: a move to over-the-counter markets would likely cut liquidity and institutional interest, and could complicate the at-the-market financing the company depends on, given the going-concern qualification in its latest filing.

Company and product background

Nexalin, incorporated in Delaware and headquartered in Houston, Texas, has traded on Nasdaq since its September 2022 IPO. Its DIFS technology delivers low-intensity electrical stimulation transcranially without drugs, implants or psychotherapy. The Gen-2 device holds regulatory approvals in China, Brazil, Oman and Israel but no FDA clearance. Nexalin's primary U.S. objective is a planned randomized, triple-blind, sham-controlled trial of its newer HALO Clarity device for moderate-to-severe insomnia, materials cite both 150- and 160-participant designs, an unresolved discrepancy, meant to support a De Novo FDA submission, with enrollment targeted for Q2 2026 and not yet confirmed as started. In May 2026, Nexalin acquired PONM, Inc., the digital-health platform behind HALO Clarity and Nexalin NeuroCare, for $1.3 million in stock issued in tranches. Nexalin also pursues a De Novo pathway for an Alzheimer's indication, planning an amended Q-Submission in Q2 2026. None of these programs has an FDA clearance to date.

Financial position

As of March 31, 2026 (its latest 10-Q), Nexalin held $1.21 million in cash plus $1.50 million in short-term investments, against current liabilities of $808,364, leaving working capital near $2.48 million. It used $1.71 million in cash for operations that quarter and posted a net loss of $2.10 million (versus $1.99 million a year earlier), against just $14,950 in quarterly revenue, down from $41,015. (One data provider cites a different trailing-twelve-month revenue figure near $276,000, an unresolved discrepancy; readers should rely on the SEC filing.) The filing cites going-concern "substantial doubt" about continuing operations. Nexalin relies on an at-the-market facility with Maxim Group, having sold roughly 1.4 million shares for $756,421 net that quarter, with about $2.85 million of ATM capacity remaining. Shares outstanding were 20,581,646 as of May 7, 2026, likely higher now given further sales. Based on quarterly burn, cash on hand would fund only a few months without more financing, an estimate, not guidance, underscoring reliance on dilutive sales.

Bull case

Bulls cite a widening set of clinical signals, the Brazil anxiety data, earlier insomnia and adolescent-depression studies, and legislative language supporting VA research into non-invasive neurostimulation, as evidence Nexalin's drug-free approach could find traction if the HALO Clarity trial succeeds and earns FDA clearance. The PONM acquisition consolidates device and software assets that could streamline the trial and later commercialization. Maxim Group has maintained a Buy rating, even after cutting its target to $2 from $4 earlier in 2026.

Risk case

The most immediate risk is binary: absent Nasdaq Hearings Panel relief, NXL would be suspended from trading August 4, 2026 and likely move to over-the-counter markets, typically depressing valuation and liquidity. Financially, the company generates negligible revenue, carries a going-concern qualification, and depends on continuous ATM sales to fund its cash burn, implying ongoing dilution. Clinically, the Brazil results come from a small, open-label, uncontrolled pilot lacking a placebo comparator or disclosed patient count, carrying limited weight that may not replicate in the blinded U.S. trial. No FDA clearance has been granted for any Nexalin indication, and both pathways remain early, pre-submission, with no guaranteed timeline.

What investors should watch next

- Outcome of the Nasdaq Hearings Panel review and whether NXL retains its listing past August 4, 2026.

Conclusion

Nexalin's Brazil data offer an incremental, if preliminary, point supporting its drug-free neurostimulation platform, arriving alongside a widening slate of FDA initiatives spanning insomnia and Alzheimer's disease. Yet its near-term fate may be decided less by clinical data than by a Nasdaq Hearings Panel: a delisting would strike at Nexalin's ability to raise the capital its going-concern position requires. Investors should treat the clinical signals as encouraging but unproven, and the balance-sheet and listing risks as immediate and material.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.